Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in pediatric asthma
NCT00283504Phase 4Completed
- Sponsor
- Children's Hospital of The King's Daughters
- Start
- Jan 2006
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Children's Hospital of The King's Daughters. Primary endpoint: Change in Sputum Inflammatory Markers at 32 weeks. Started Jan 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00283504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283504.